Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy (CROSBI ID 222410)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Mandić, Dario ; Božina, Nada ; Mandić, Sanja ; Samardžija, Marina ; Milostić-Srb, Andrea ; Rumora, Lada VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy // International journal of clinical pharmacology and therapeutics, 53 (2015), 11; 905-913. doi: 10.5414/CP202424

Podaci o odgovornosti

Mandić, Dario ; Božina, Nada ; Mandić, Sanja ; Samardžija, Marina ; Milostić-Srb, Andrea ; Rumora, Lada

engleski

VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy

The objective was to determine the impact of VKORC1 polymorphisms on warfarin anticoagulant therapy (stable warfarin maintenance dose, time required to reach therapeutic dose and time spent in therapeutic range) and its adverse events (overanticoagulation and bleeding events, time to first overanticoagulation or bleeding event, and therapy for bleeding events) in Croatian patients. Blood samples were collected from 186 patients on stable warfarin therapy. VKORC1 1173C>T and VKORC1 – 1639G>A gene polymorphisms were analyzed using real-time PCR. Prothrombin time international normalized ratio (INR) values were determined and overanticoagulation as well as bleeding events were recorded. Both tested VKORC1 gene polymorphisms (VKORC1 1173C>T and VKORC1 –1639G>A) were in perfect linkage disequilibrium. Genotype analysis showed that 33.9% of patients were homozygous for wild- type, 46.8% were heterozygous and 19.4% were homozygous for the variant allele. We have found a statistically significant difference between variantallele carriers and wild-type patients in stable warfarin maintenance dose (p < 0.001) and incidence of bleeding events (p = 0.040). Patients homozygous for variant-allele were more likely to experience an overanticoagulation event in the first 30 days of therapy (p = 0.040). Our study showed that VKORC1 1173C>T and VKORC1 –1639G>A gene polymorphisms are associated with stable warfarin maintenance dose and adverse events of warfarin therapy.

VKORC1; warfarin; genetic polymorphism; pharmacogenetics

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

53 (11)

2015.

905-913

objavljeno

0946-1965

10.5414/CP202424

Povezanost rada

Temeljne medicinske znanosti, Farmacija

Poveznice
Indeksiranost